->

July 22, 2018 – By Carolyn Hewitt

Analysts are waiting for Sol-Gel Technologies Ltd. (NASDAQ: SLGL) is reporting $ -0.47 EPS on August 21st. After having $ -0.39 EPS before, Sol Analysts at -Gel Technologies Ltd. see earnings per share growth of 20.51%. The stock rose 1.47% or $ 0.1 over the last trading day, reaching $ 6.91. Approximately 4,141 shares were traded. Sol-Gel Technologies Ltd. (NASDAQ: SLGL) has 0.00% since July 22, 2017 and is. It underperformed the S & P500 by 12.57%.

Sol-Gel Technologies Ltd., a specialty pharmaceutical company in the clinical phase, focuses on the development and commercialization of topical dermatological products based on its proprietary microencapsulation system in Israel. The company has a market capitalization of $ 130.94 million. The company's leading product candidates include TWIN and SIRS-T, which have completed Phase II clinical trials for the treatment of acne vulgaris; and VERED, which has completed Phase II clinical trials for the treatment of papulopustular rosacea. He currently has negative gains. He is also involved in the development of generic dermatological drug products.

More news for Sol-Gel Technologies Ltd. (NASDAQ: SLGL) was recently published by: Benzinga.com, which published: "A look at 2018 IPOs" on July 05, 2018. The article in Streetinsider.com titled: "UPDATE: HC Wainwright Launches Sol Gel Technologies Ltd. (SLGL) at Buy" and published on July 16, 2018 is another important article.

Receive News & Notes via Email – Enter your email address below to receive a daily concise summary of the latest news and updates. badysts' notes with our free daily e-newsletter.